INCHEON, Corea del Sud–(BUSINESS WIRE)–Celltrion ha annunciato oggi che la Commissione europea (CE) ha concesso l’autorizzazione all’immissione in commercio di due prodotti,: Eydenzelt® (CT-P42, aflibercept), un biosimilare di Eylea® per il trattamen…
Author: Business Wire
Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet
GENEVA–(BUSINESS WIRE)–Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief with Its Longest Lasting Formula Yet
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has…
Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financ…
EyeCare Partners Announces New Physician Leadership Appointments
ST. LOUIS–(BUSINESS WIRE)– #elevatingeyeare–EyeCare Partners (ECP) is pleased to announce the appointment of Michael Nordlund, M.D., Ph.D., as Chief Medical Officer (CMO) and Joseph Gira, M.D., as Chief Physician Relations Officer (CPRO), strengthen…
Seonix Bio Announces US Launch of SightScore, the First Commercially Available Clinical Polygenic Risk Score Testing Service for Glaucoma
SAN DIEGO–(BUSINESS WIRE)–Seonix Bio, a leader in the development of genetic testing for glaucoma, today announced the U.S. launch of SightScore, the first commercially available clinical polygenic risk score testing service for primary open-angle gl…
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension
GENEVA–(BUSINESS WIRE)–Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2024 financial results. “Underpin…
Celltrion兩款生物相似性藥品獲歐盟委員會核准，進一步擴大其在歐盟的生物相似性藥品組合
韓國仁川–(BUSINESS WIRE)–(美國商業資訊)– Celltrion今日宣布，歐盟委員會(EC)已核准兩種生物相似性藥品的三款產品上市，分別為： Eydenzelt® (CT-P42, aflibercept)，一種Eylea®的生物相似性藥品，用於治療多種視網膜疾病，包括新生血管性（濕性）年齡相關性黃斑變性(AMD)、視網膜靜脈阻塞（RVO，分支RVO或中心RVO）後的黃斑水腫、糖尿病性黃斑水腫(DME)以及近視性脈絡膜新生血管病變（近視性CNV）；以及Stoboclo® 和Os…
セルトリオンが欧州委員会による承認獲得、EUで2つのバイオシミラー製品のポートフォリオを拡大
韓国、仁川–(BUSINESS WIRE)–（ビジネスワイヤ） — （ビジネスワイヤ） — セルトリオンは、欧州委員会（EC）から2つのバイオシミラーにおいて3つの製品の販売承認を取得したと発表しました。承認を受けたEydenzelt® （CT-P42、アフリベルセプト）は、Eylea®のバイオシミラーであり、新生血管（滲出型）加齢黄斑変性（AMD）、網膜静脈閉塞症（RVO：分枝RVOまたは中心RVO）に伴う黄斑浮腫、糖尿病黄斑浮腫（DME）、および近視性脈絡膜新生血管（myopic CNV…
Celltrion breidt haar portfolio biosimilaire geneesmiddelen in de Europese Unie uit na goedkeuring van de Europese Commissie van twee biosimilars
INCHEON, Zuid-Korea–(BUSINESS WIRE)–Celltrion maakte vandaag bekend dat de Europese Commissie (EC) een vergunning heeft verleend voor het in de handel brengen van drie producten in twee biosimilars: Eydenzelt® (CT-P42, aflibercept), een biosimilar di…
Mit der Zulassung von zwei weiteren Biosimilars erweitert Celltrion sein Biosimilar-Portfolio in der EU
INCHEON, Südkorea–(BUSINESS WIRE)–Wie Celltrion heute mitteilte, hat die Europäische Kommission die Marktzulassung für zwei Biosimilars erteilt:: Eydenzelt® (CT-P42, Aflibercept), ein Biosimilar zu Eylea®, zur Behandlung verschiedener Netzhauterkrank…
Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars
INCHEON, South Korea–(BUSINESS WIRE)–Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® (CT-P42, aflibercept), a biosimilar to Eylea® to treat multiple…
Celltrion élargit son portefeuille de produits biosimilaires dans l’Union européenne suite à l’autorisation de deux nouvelles molécules biosimilaires par la Commission européenne
INCHEON, Corée du Sud–(BUSINESS WIRE)–Celltrion a annoncé aujourd’hui que la Commission européenne (CE) a accordé une autorisation de mise sur le marché pour trois produits dont deux molécules biosimilaires : Eydenzelt® (CT-P42, aflibercept), un médi…
National Vision’s 20/20 Quest Foundation Grants $25,000 to Optometry Giving Sight to Support Global Vision Care Initiatives
DULUTH, Ga.–(BUSINESS WIRE)–National Vision, Inc. announced today that its charitable foundation, 20/20 Quest, has awarded a $25,000 grant to Optometry Giving Sight (OGS). The funding supports OGS’s ongoing mission to combat preventable blindness and…
GeminiBio Appoints Mike Stella to Board
WEST SACRAMENTO, Calif.–(BUSINESS WIRE)–Gemini Bioproducts, LLC (“GeminiBio”), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a Fort Lauderdale-based healthcare pr…
Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration
FORT LEE, N.J.–(BUSINESS WIRE)–Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD), today announced that th…
Eye Health America Further Expands in Southwest Florida with the Acquisition of Quigley Eye Specialists
FORT MYERS, Fla.–(BUSINESS WIRE)– #eyecare–Eye Health America (EHA), a leading integrated eye care platform in the Southeastern United States, is excited to announce its acquisition of Quigley Eye Specialists (QES), a perfect complement to Eye Cente…
Perfect Moment Expands Accessories Line with Puffer Tote Bags and Sunglasses
LONDON–(BUSINESS WIRE)–Perfect Moment Ltd. (NYSE American: PMNT), the high-performance, luxury skiwear and lifestyle brand that fuses technical excellence with fashion-led designs, has officially launched its new puffer tote bag and sunglass collecti…
“Father of Surgical Robotics” Dr. Fred Moll Joins ForSight Robotics Board of Directors
YOKNEAM ILLIT, Israel–(BUSINESS WIRE)– #Innovation–ForSight Robotics expands leadership team with Dr. Fred Moll, “father of surgical robotics,” joining Board of Directors; appoints VP R&D and VP People